Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 8/20 | 0.42 |
| ▸ | FURIN | P09958 | 3/20 | 0.38 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.36 |
| ▸ | GRB2 | P62993 | 1/20 | 0.35 |
| ▸ | MAP1LC3B | Q9GZQ8 | 2/20 | 0.35 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.35 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17550383 | 0.94 | PTPN1 (0.38) | PTPN1FURINMDM2SIRT5SSTR3 | |
| SCHEMBL17541276 | 0.94 | PTPN1 (0.38) | PTPN1FURINMDM2SIRT5SSTR3 | |
| SCHEMBL17541309 | 0.93 | KLK7 (0.38) | PTPN1FURINMDM2SSTR3 | |
| SCHEMBL22442662 | 0.93 | PTPN1 (0.43) | PTPN1FURINGRB2SIRT5SSTR3 | |
| SCHEMBL30361583 | 0.93 | PTPN1 (0.43) | PTPN1FURINGRB2SIRT5SSTR3 | |
| SCHEMBL22442664 | 0.93 | PTPN1 (0.43) | PTPN1FURINGRB2SIRT5SSTR3 | |
| SCHEMBL30483317 | 0.93 | PTPN1 (0.42) | PTPN1FURINMAP1LC3BSSTR3 | |
| SCHEMBL12094377 | 0.92 | HTR2A (0.40) | PTPN1FURINMAP1LC3BSIRT5SSTR3 | |
| SCHEMBL12944195 | 0.92 | HTR2A (0.40) | PTPN1FURINMAP1LC3BSIRT5SSTR3 | |
| SCHEMBL2734925 | 0.92 | HTR2A (0.40) | PTPN1FURINMAP1LC3BSIRT5SSTR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250114441-A1 | POLYMERIC VACCINE FOR OPIOID ADDICTION | THE JOHNS HOPKINS UNVERSITY | 2025-04-10 | — | — | US | disclosed |
| US-20230414775-A1 | TUBULYSINS AND PROTEIN-TUBULYSIN CONJUGATES | REGENERON PHARMACEUTICALS, INC. | 2023-12-28 | — | — | US | disclosed |
| EP-4171653-A2 | TUBULYSINS AND PROTEIN-TUBULYSIN CONJUGATES | Regeneron Pharmaceuticals, Inc. (US) | 2023-05-03 | — | — | EP | disclosed |
| US-20230069722-A1 | TUBULYSINS AND PROTEIN-TUBULYSIN CONJUGATES | REGENERON PHARMACEUTICALS, INC. | 2023-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230069722-A1 | TUBULYSINS AND PROTEIN-TUBULYSIN CONJUGATES | SDCBP, TEK, TEKT1 | PTPN1 1817/4885FURIN 2008/4885MDM2 4715/4885 |
| US-20230414775-A1 | TUBULYSINS AND PROTEIN-TUBULYSIN CONJUGATES | SDCBP, TEK, TEKT1 | PTPN1 1817/4885FURIN 2008/4885MDM2 4715/4885 |
| US-20250114441-A1 | POLYMERIC VACCINE FOR OPIOID ADDICTION | OPRM1, OPRK1, OPRL1 | PTPN1 802/4885FURIN 1748/4885MDM2 4514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.